The combination of a revenue beat, strong EPS growth, and upward guidance revision is a clear positive catalyst. The $22M debt prepayment signals improving balance sheet health. Watch for continued margin expansion and cash flow generation as the company executes on its 2026 plan.
Price Chart
Executive Summary
Bioventus reported Q1 2026 revenue of $132.1M (+6.6% YoY) and GAAP EPS of $0.04, improving from a -$0.04 loss in the prior year. The company raised its full-year 2026 Adjusted EPS guidance to $0.75-$0.79 and Cash from Operations guidance to $84M-$89M, while reaffirming revenue guidance of $600M-$610M. The beat on consensus estimates and upward guidance revision signal accelerating operational momentum and debt reduction progress.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of $132.1M (+6.6% YoY) vs consensus $129.9M
- GAAP EPS of $0.04 vs -$0.04 YoY; Non-GAAP EPS of $0.15 vs $0.08 YoY (+88%)
- Adjusted EBITDA of $23.9M (+24% YoY)
- Raised FY2026 Adjusted EPS guidance to $0.75-$0.79 (from $0.73-$0.77)
- Raised FY2026 Cash from Operations guidance to $84M-$89M (from $82M-$87M)
- Reaffirmed FY2026 revenue guidance of $600M-$610M (+6-7% growth)
- Made $22M discretionary principal prepayment on term loan in March 2026
- Cash from operations of $8.9M vs -$19.3M cash outflow in prior-year period
Financial Impact
Q1 revenue beat consensus by ~$2.2M; Non-GAAP EPS of $0.15 represents an 88% YoY increase; FY2026 Adjusted EPS guidance raised by $0.02 at midpoint
Risk Factors
- Revenue growth partially driven by a $4.2M favorable one-time rebate benefit from a billing process change
- Restructuring costs of $454K in the quarter indicate ongoing cost optimization
- Cash balance declined to $35.8M from $51.2M at year-end due to debt prepayment
- Guidance assumes continued above-market growth in a competitive medical device market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001665988-26-000026 |
| Document: bvs-20260506.htm | 0001665988-26-000026 |
| Document: 0001665988-26-000026-index-headers.html | 0001665988-26-000026 |
| Document: 0001665988-26-000026-index.html | 0001665988-26-000026 |
| Document: 0001665988-26-000026.txt | 0001665988-26-000026 |
| 8-K Data (Synthetic) | 0001665988-26-000026 |
Track record
18 reports on BVS
2 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +37.19% at T+60 after the May 8, 2026 report. 3 of 7 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $10.66 Now $10.46 −1.88% settles Feb 11
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $10.61 Now $10.46 −1.41% settles Feb 4
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $10.95 Now $10.46 −4.43% settles Feb 1
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $14.65 Now $10.46 −28.60% settles Jan 26
- Aug 15, 202613w ago Institutional Cluster Mixed 5/10 Entry $13.88 to $11.02 Now $10.46 −24.64% ▼ −20.64% −17.88% vs SPY
- Aug 5, 202614w ago 8-K Bullish 7/10 No price data
- Aug 5, 202614w ago Press Release Bullish 7/10 Entry $15.26 to $14.86 Now $10.46 −31.45% ▼ −2.62% −2.81% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $8.68 to $14.07 Now $10.46 −20.51% ▼ −62.10% −57.70% vs SPY
- Jun 2, 202623w ago Press Release Bearish 6/10 Entry $8.11 to $13.97 Now $10.46 −28.98% ▼ −72.26% −71.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers